Fractalkine as a marker for assessment of severe acute pancreatitis

Journal of Digestive Diseases

Volumn 13, Issue 4, 2012, Pages 225-231

  Huang, Li Ya ^a,b   Chen, Ping ^a   Xu, Ling Xiao ^a   Zhou, Yu Fen ^a   Li, Wei Guang ^a   Yuan, Yao Zong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Chemokine; Fractalkine; Inflammation; Severe acute pancreatitis

Indexed keywords

FRACTALKINE; MESSENGER RNA;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE ACUTE PANCREATITIS; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; CHEMOKINE CX3CL1; DISEASE MODELS, ANIMAL; GENE EXPRESSION; KIDNEY; LUNG; PANCREAS; PANCREATITIS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 84863356740     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2012.00580.x     Document Type: Article

References (27)

1. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000; 47: 546-52.
2. Harrison DA, D'Amico G, Singer M. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. Crit Care Med 2007; 35: 1703-8.
3. Johnson CD, Kingsnorth AN, Imrie CW etal. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-9.
4. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai I. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
5. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001; 159: 1521-30.
6. Lee SJ, Namkoong S, Kim YM etal. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNos-dependent signal pathways. Am J Physiol Heart Circ Physiol 2006; 291: H2836-46.
7. Efsen E, Grappone C, DeFranco RM etal. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002; 37: 39-47.
8. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002; 62: 488-95.
9. Chen P, Yuan Y, Wang S, Zhan L, Xu J. Captopril, an Angiotensin-converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase 9. Tohoku J Exp Med 2006; 209: 99-107.
10. Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg 1994; 167: 214-8; discussion 218-9.
11. Zhang XP, Zhang J, Ma ML etal. Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary Pancreat Dis Int 2010; 9: 83-7.
12. Yubero S, Ramudo L, Manso MA, De Dios I. Mechanisms of dexamethasone-mediated chemokine downregulation in mild and severe acute pancreatitis. Biochim Biophys Acta 2009; 1792: 1205-11.
13. Inoue A, Hasegawa H, Kohno M etal. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52: 1522-33.
14. Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO. Fractalkine expression in human renal inflammation. J Pathol 2002; 196: 85-90.
15. Zhang XP, Wang L, Zhou YF. The pathogenic mechanism of severe acute pancreatitis complicated with renal injury: a review of current knowledge. Dig Dis Sci 2008; 53: 297-306.
16. Kingsnorth A. Role of cytokines and their inhibitors in acute pancreatitis. Gut 1997; 40: 1-4.
17. Al Mofleh IA. Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J Gastroenterol 2008; 14: 675-84.
18. Papachristou GI, Whitcomb DC. Inflammatory markers of disease severity in acute pancreatitis. Clin Lab Med 2005; 25: 17-37.
19. Rettally CA, Skarda S, Garza MA, Schenker S. The usefulness of laboratory tests in the early assessment of severity of acute pancreatitis. Crit Rev Clin Lab Sci 2003; 40: 117-49.
20. Sandberg AA, Borgström A. Early prediction of severity in acute pancreatitis. Is this possible? JOP 2002; 3: 116-25.
21. Sochor M, Richter S, Schmidt A, Hempel S, Hopt UT, Keck T. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Digestion 2009; 80: 65-73.
22. Chen C, Xu S, Wang WX etal. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res 2009; 40: 79-88.
23. Chen XJ, Cheng DY, Yang L, Xia XQ, Guan J. Effect of breviscapine on fractalkine expression in chronic hypoxic rats. Chin Med J (Engl) 2006; 119: 1465-8.
24. Perros F, Drofmüller P, Souza R etal. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937-43.
25. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-20.
26. Friedwald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-91.
27. Oh DJ, Dursun B, He Z etal. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008; 294: F264-71.